Autoimmunity refers to the phenomenon that the body's immune system produces antibodies
or sensitized lymphocytes to its own tissues to cause an immune response. Immune …

Autophagy is a highly conserved lysosomal degradation system that involves the creation of
autophagosomes, which eventually fuse with lysosomes and breakdown misfolded proteins …

Importance Vitiligo can have profound effects on patients and is often associated with other
autoimmune comorbid conditions. It is important to understand the current prevalence of …

Abstract The Food and Drug Administration (FDA) has authorized Ruxolitinib (Opzelura), as
first at-home treatment for non-segmental vitiligo, an autoimmune condition that causes …

Vitiligo is a common chronic autoimmune skin disorder featured with depigmented patches
and underlying destruction of melanocytes in the lesional skin. Multiple factors and …

Vitiligo is an acquired immune-mediated disorder of pigmentation clinically characterized by
well-defined depigmented or chalk-white macules and patches on the skin. The prevalence …

Vitiligo, a common depigmenting cutaneous condition, is thought to affect 0.5%-2% of the
world's population. During this condition, melanocytes are selectively lost, resulting in non …

Vitiligo is a noncontagious autoimmune skin depigmenting disease. Regulatory T cells
(Tregs) play a key role in maintaining peripheral tolerance; however, Tregs' number …

Epidermal melanocyte loss in vitiligo, triggered by stresses ranging from trauma to emotional
stress, chemical exposure or metabolite imbalance, to the unknown, can stimulate oxidative …

Objective To evaluate the clinical efficacy and safety of baricitinib, a Janus kinase (JAK)
inhibitor, in treating patient with progressing vitiligo, and to further explore the regulation of …